Mesoporous silica nanoshell (MSN) coating has been demonstrated as a versatile surface modification strategy for various kinds of inorganic functional nanoparticles, such as gold nanorods (GNRs), to achieve not only improved nanoparticle stability but also concomitant drug loading capability. However, limited drug loading capacity and low tumor accumulation rate in vivo are two major challenges for the biomedical applications of MSN-coated GNRs (GNR@MSN). In this study, by coating uniformly sized GNRs with MSN in an oil-water biphase reaction system, we have successfully synthesized a new bacteria-like GNR@MSN (i.e., bGNR@MSN) with a significantly enlarged pore size (4e8 nm) and surface area (470 m 2 /g). After PEGylation and highly efficient loading of doxorubicin (DOX, 40.9%, w/w), bGNR@MSN were used for positron emission tomography (PET, via facile and chelator-free 89 Zr-labeling) and photoacoustic imaging-guided chemo-photothermal cancer therapy in vivo. PET imaging showed that 89 Zr-labeled bGNR@MSN(DOX)-PEG can passively target to the 4T1 murine breast cancer-bearing mice with high efficiency (~10 %ID/g), based on enhanced permeability and retention effect. Significantly enhanced chemo-photothermal combination therapy was also achieved due to excellent photothermal effect and near-infrared-light-triggered drug release by bGNR@MSN(DOX)-PEG at the tumor site. The promising results indicate great potential of bGNR@MSN-PEG nanoplatforms for future cancer diagnosis and therapy.
Introduction
Gold nanorods (GNRs), with anisotropic shape, tunable size, intrinsic biocompatibility and strong optical absorption at nearinfrared (NIR) wavelength range are one of the most widely studied noble metal nanomaterials for potential biomedical applications [1e4], including but not limited to biomedical imaging [5, 6] , drug delivery [7e11], biomolecular sensing [12] and photothermal therapy [8,13e16] . However, biomedical application of GNRs have been limited due to poor solubility, potential cytotoxicity from the residual surface surfactants [17] and suboptimal imaging and drug loading capacities [18, 19] . Mesoporous silica nanoshell (MSN) with large surface area, tunable size and high pore volume has been widely used as a coating material for inorganic functional nanoparticles, including GNRs, to improve their in vivo stability and offer drug loading capability [20, 21] . Photothermal therapy (PTT) has been developed as a promising strategy for cancer treatment [13e16] and other biomedical applications [22e24] which employ the heat generated from the light-absorbing agents accumulated in the tissue or tumor area. Some reports have demonstrated the applications of MSN coated-GNRs (GNR@MSN) for combining photothermal therapy with chemotherapy (chemo-photothermal therapy) to achieve synergistic anticancer effects [10, 13, 25] .
Nevertheless, the pore size and surface area of previously reported GNR@MSN are usually in the range of 0.5e4.0 nm and 50e350 m 2 /g, respectively [4, 13, 25] which led to limited drug loading capacity and consequently suboptimal therapeutic outcomes. Large pore (>5 nm), biodegradable mesoporous silica nanoparticles with greater surface areas can be easily synthesized via a facile oil-water biphase stratification approach [26, 27] . However, it's still a major challenge to coat uniform mesoporous silica layers with large pore size (>5 nm), high pore volume and surface area on the surface of GNRs and suited for in vivo biomedical applications [28] . In addition, previous reports have employed optical imaging or inductively coupled plasma mass spectrometry techniques to study the biodistribution of GNR@MSN in vivo, which yield partial information or are very invasive requiring many animals to be sacrificed [14, 18] . Thus, more sensitive, non-invasive and dynamic imaging approaches are desirable for the systematic studies of in vivo pharmacokinetics of GNR@MSN. Positron emission tomography (PET) is a highly sensitive and noninvasive radionuclide imaging method which can provide quantitative assessment of in vivo nanoparticles biodistribution and pharmacokinetics [29, 30] . Photoacoustic (PA) imaging, with rich optical contrast, deep penetration and high ultrasonic spatial resolution, has received immense attention recently in the field of cancer diagnosis and therapy [31] . Combining PET with PA imaging could overcome the limitations of single modality and improve the diagnostic accuracy [32] . In addition, with one nanoplatform acting as both the contrast agent and therapeutic agent, specific imagingguided cancer therapy can be easily realized [33] .
In this study, we develop a novel strategy to fabricate GNR@MSN multifunctional nanoplatforms with a bacteria-like morphology. As developed bacteria-like GNR@MSN (bGNR@MSN) demonstrates large pore size, high pore volume and surface area, resulting in high doxorubicin (DOX) loading efficiency (40.9%, w/w). After PEGylation and chelator-free labeling with radioisotope zirconium-89 ( 89 Zr, t 1/2 ¼ 78.4 h) [34] , PET and PA imaging-guided in vivo cancer therapy was subsequently conducted. The results showed chemophotothermal cancer treatment mediated by bGNR@MSN(DOX)-PEG exhibited significantly enhanced therapeutic efficacy in 4T1 murine breast tumor-bearing mice.
Experimental

Reagents and materials
All reagents were analytical or higher grade. Gold (III) chloride solution (HAuCl 4 $3H 2 0), tetraethyl orthosilicate (TEOS), cetyltrimethylammonium bromide (CTAB), cetyltrimethylammonium chloride (CTAC), AgNO 3 , NaBH 4 , L-ascorbic acid, oleic acid, [3-(4,5-dimethylthiazol-2-yl)-3,5-diphenytetrazolium bromide] (MTT), (3-mercatopropyl)trimethoxy-silane (MPTMS), (3-aminopropyl) triethoxysilane (APS), triethylamine (TEA) and Chelex 100 resin (50e100 mesh) were purchased from Sigma-Aldrich (St. Louis, MO). Succinimidyl carboxymethyl PEG maleimide (SCM-PEG-Mal; molecular weight: 5 kDa) was purchased from Creative PEGworks (Winston Salem, NC). All buffers and water were Millipore grade and pre-treated with Chelex 100 to remove heavy metal. All other reaction chemicals and reagent were purchased from Thermo Fisher Scientific (Fair Lawn, NJ).
Characterization
Transmission electron microscopy (TEM) images were obtained by Tecnai TF-30, 300 kV field emission. Nitrogen adsorptiondesorption isotherms were measured at 77.3 K using a Quantachrome NovaWin2 system. Surface areas and pore size were determined by the BET (Barrett-Joyner-Halenda) method. Size and zeta analysis were performed on Nano-ZS90 Zetasizer (Malvern Instruments Ltd.). UVevis spectra were recorded on Agilent Cary 60 spectrophotometer. Photothermal images were recorded by a FLIR™ E50 camera.
Synthesis of GNRs and bGNR@MSN-PEG
GNRs were synthesized according to the seed-mediated growth method [35] with the surfactant CTAC and oleic acid (see Supporting Information). Mesoporous silica layers were coated on the surface of GNRs by an oil-water biphase reaction approach [26] . In a typical process, 10 mL of CTAC solution (25 wt%), 10 mL GNRs water solution (0.2 mg/mL) and 0.1 g of TEA were added to 36 mL of water and stirred gently at 60 C for 1 h in a 100 mL round-bottom flask. 10 mL of 1 mM MPTMS ethanol solution was added. Then ten milliliters of (5% v/v) TEOS in cyclohexane was carefully added to the CTAC-TEA aqueous solution and kept at 60 C in a water bath for 12 h. Afterward, bGNR@MSN were collected by centrifugation (at 9000 rpm for 10 min). The precipitates were re-dispersed and washed by 1 wt % NaCl/methanol solution to remove CTAC for five times (24 h/time).
Surface amino modification was achieved by adding 1 mL of APS to 10 mL of bGNR@MSN in absolute ethanol solution. The mixture was kept in 35 C water bath and stirred for 72 h, followed by repeated centrifugation and washing with ethanol to remove any unreacted APS. bGNR@MSN-NH 2 was then dispersed in water, 5 mg SCM-PEG 5k -Mal was added to the solution and reacted for 2 h. Finally, bGNR@MSN-PEG were collected by centrifugation (9000 rpm for 10 min) and washed with water for 3 times to remove excess PEG.
Photothermal effect of bGNR@MSN and DOX loading and release
Different concentrations of bGNR@MSN in water solution were irradiated by a NIR laser (808 nm, 0.25 W/cm 2 ) for 10 min and cooled down for another 10 min. The temperature of the solution was recorded by using a digital thermometer. Pure mesoporous silica nanoparticles (MSNs) solution (3 mg/mL) and water were used as controls. DOX was loaded into bGNR@MSN-PEG by mixing the drug with bGNR@MSN-PEG in a PBS buffer at different pH values (5.3 and 7.4) for 24 h, and unloaded DOX was removed with the supernatant after centrifugation (9000 rpm for 10 min). The precipitates were washed by PBS until the supernatant became colorless. The DOX concentration in all supernatants was recorded to calculate the drug loading efficiency. For drug release experiments, bGNR@MSN(DOX)-PEG was suspended in PBS at different pH values (5.3 and 7.4) in dialysis tubes of 10 kDa MWCO (molecular weight cut off). At each time point (0.5 h, 3 h, 6 h, 12 h and 24 h), bGNR@MSN(DOX)-PEG solution was irradiated by a NIR laser (0.5 W/cm 2 ) for 5 min. 0.5 mL dialysis solution was removed after NIR irradiation, and the same volume of PBS buffer was added back in. The amount of DOX was measured by UVevis spectrometer at a wavelength of 490 nm.
Cell lines and animal model
4T1 murine breast cancer cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured as previously described [36] . Cells were used for in vitro and in vivo experiments when they reached~80% confluence. All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. 4e5 weeks old female BALB/c mice (Envigo, Indianapolis, IN) were injected with 2 Â 10 6 4T1 cells in the flank (for PET and PA imaging) or shoulder (for photothermal imaging) to generate the 4T1 breast cancer model. The BALB/c mice were used for in vivo cancer treatment experiments when the tumor reached 6e8 mm in diameter.
In vitro photothermal and chemo-photothermal therapy
Murine breast cancer 4T1 cells were cultured at 37 C and with 5% CO 2 in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were seeded into a 96-well plate with 10 6 cells per well and then incubated for 24 h at 37 C under 5% CO 2 . Different concentration (2 mg/mL, 5 mg/ mL and 10 mg/mL) of bGNR@MSN, DOX and bGNR@MSN(DOX)-PEG (with equivalent DOX concentration) in cell culture media solutions were added to the wells and incubated for 4 h before the treatments. For the photothermal therapy and chemo-photothermal therapy, the cells were irradiated by a NIR laser (0.5 W/cm 2 for 5 min) and followed by further incubation for 12 h. Cell viability was measured using a typical MTT assay.
For trypan blue staining, different concentration (0 mg/mL, 10 mg/ mL, 40 mg/mL and 80 mg/mL) of bGNR@MSN-PEG in a PBS solution were added to a cell culture plate containing 4T1 cells and cells were exposed to NIR laser with a power density of 0.5 W/cm 2 for 5 min and incubated for 4 more hours. Afterward, the cells were stained with 0.4% trypan blue solution for 10 min and washed by with PBS three times. The cell morphology was observed by an inverted optical microscope (Nikon, Eclipse Ti-U, Japan).
2.7.
89
Zr radiolabeling, PET and PA imaging
Chelator-free 89 Zr labeling method was used for radiolabeling bGNR@MSN as reported previously by our group [34] . In a typical study, 500 mL of bGNR@MSN-PEG (5 mg) was directly mixed with 1 mCi (or 37 MBq) of 89 Zr-oxalate at 60 C for 2 h with constant shaking. The final pH value of the solution was adjusted to 7e8 with Na 2 CO 3 (1 M).
Zr labeling yield was monitored by thin layer chromatography (TLC).
Zr-bGNR@MSN-PEG was collected by centrifugation (9000 rpm, 10 min) to remove the free 89 Zr in the supernatant and finally dispersed in PBS for in vivo applications. The labeling yield was monitored and quantified by using TLC.
PET imaging scans of 4T1 tumor-bearing mice (4 mice per group) were performed at various time points post-injection (p.i.) of 4e7 MBq of 89 Zr-bGNR@MSN(DOX)-PEG via the tail vein, on a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.). Detailed procedures for data acquisition, image reconstruction, and region-of-interest (ROI) analysis of the PET imaging data have been reported previously [37] . Quantitative PET data of the 4T1 tumors and major organs were presented as percentage injected dose per gram of tissue (%ID/g).
To validate that the ROI values of PET imaging reflected the radioactivity distribution in mice, ex vivo biodistribution studies were conducted at 24 h p. i. After euthanizing the mice, 4T1 tumors, blood and major organs/tissues were collected and wet weighed. The radioactivity in the tissue or blood was measured by a gamma counter (PerkinElmer) and presented as %ID/g (mean ± SD).
PA imaging was performed by Vevo LAZR Photoacoustic Imaging System (VisualSonics, Inc. Toronto, Canada) with a laser excitation wavelength of 808 nm and a focal depth of 100 mm. 4T1 tumorbearing mice were scanned before the injection (control) and 24 p. i. with 150 mL bGNR@MSN(DOX)-PEG PBS solution (2 mg/mL).
In vivo chemo-photothermal therapy
For in vivo treatment studies, 4T1 tumor-bearing mice were randomly divided into 5 treatment groups, when the average volume of the tumors reach~150 mm Tumor temperature and thermal images were monitored and visualized by a FLIRTM E50 camera. Hematoxylin-eosin (H&E) staining of tumors was performed at 24 h after different treatments to compare the therapeutic efficacy. The tumor volumes were recorded every other day for 14 days by caliper measurements.
Results and discussion
bGNR@MSN synthesis and characterizations
The synthetic strategy of bGNR@MSN is shown in Fig. 1 . Firstly, CTAC and oleic acid were used as surfactants for highly efficient and high yield the synthesis of GNRs by seed-mediated growth method [35] . TEOS was used as silica precursor and the coating process was conducted in an oil-water biphase system. Amino-modification and PEGylation of the surface mesoporous silica layer were then conducted for further biomedical applications. DOX was finally loaded in the mesopores of bGNR@MSN. In our strategy, the 808 nm NIR light was not only used to convert the light to heat to generate local hyperthermia, but also as the external stimulus to accelerate the release of DOX for the synergistic chemo-photothermal therapy.
The morphology and structure of GNRs and bGNR@MSN were characterized by TEM as shown in Fig. 2a and b . The average length and width of the obtained surface CTAC-coated GNRs were 60.5 ± 5.3 nm and 16.6 ± 1.9 nm, respectively ( Fig. 2a) with an aspect ratio of about 3.7. Inspired by the fabrication of dendritic mesoporous silica nanospheres [26] , the surface mesoporous silica coating process of GNRs was achieved in an oil-water biphase reaction system. Cyclohexane was chosen as hydrophobic solvent in the upper oil phase with TEOS (silica precursor), while the lower aqueous phase consists of cationic CTAC as a template and MPTMS promoting the silica assembly on GNRs surface. After coating with mesoporous silica layer, the average length and width of bGNR@MSN increased to 104.6 ± 5.6 nm and 68.6 ± 5.2 nm, respectively. Interestingly, the morphology of as-synthesized bGNR@MSN nanoparticles was observed to be very similar to some prokaryotic bacteria cells (e.g., E. coli), with the outside mesoporous silica layer (Fig. 2c) resembling the bacterial pili. This unique morphology is different from previously reported conventional GNR@MSN synthesized via a one-phase system [11, 13, 15, 16, 18] . The thickness of the mesoporous silica layer can be controlled by altering the reaction time. Increasing the time from 12 to 24 h would increase the thickness of MSN layer from 23.5 ± 2.3 nm (Fig. 2c) to 45.1 ± 3.8 nm (Fig. 2d) . In this study, bGNR@MSN with shell thickness of 23.5 nm was chosen for subsequent characterization and biomedical applications.
The N 2 adsorption-desorption isotherm of bGNR@MSN is shown in Fig. 3a and Fig. S6 . The primary pore size distribution (Fig. 3a  inset) [38] ), probably because the silica frameworks on the surface of bGNR@MSN are less dense with lower degree of cross-linking than regular GNR@MSN synthesized in a homogeneous system [26] . GNRs, bGNR@MSN and DOX-loaded bGNR@MSN (i.e., bGNR@MSN(DOX)) were studied by UVevis absorption spectroscopy (Fig. 3b) . CTAC-capped GNRs [35] in this work exhibited a strong longitudinal surface plasmon resonance (SPR) band at around 805 nm, which was red-shifted by about 15 nm after the coating of mesoporous silica layer, possibly due to the fact that local refractive index of silica layer is higher than water [39] . After loading of DOX, an enhanced absorption peak appeared at around 500 nm, which was consistent with previous studies [13] .
To prevent aggregation in physiological solution and increase the blood circulation half-life of the final product for enhanced in vivo passive tumor targeting efficiency [32] , PEGylation process was conducted on the surface of bGNR@MSN. After PEGylation, the average hydrodynamic diameter of bGNR@MSN was further increased from 126.1 nm to 135.9 nm (Fig. 3c) as measured by the dynamic light scattering (DLS). Fig. 3d further showed the change of surface charge after each surface modification. The surface charge of CTAC-capped GNRs in water (pH ¼ 6) were found to be 35.9 ± 3.7 mV, which changed to À23.8 ± 2.5 mV after the coating of silica layers. The surface charge of bGNR@MSN then changed from negative to positive after the surface amination step. The final PEGylated bGNR@MSN was found to be slightly negatively charged (À4.3 ± 0.9 mV) when suspended in PBS solution (pH 7.4).
Photothermal effect of bGNR@MSN and NIR light triggered DOX release
The photothermal effects of bGNR@MSN at different concentration were compared in Fig. 4a . Dendritic MSNs with similar mesoporous silica structure [26] was synthesized as the control. Upon 808 nm NIR laser irradiation at a power density of 0.25 W/ cm 2 , the temperature of bGNR@MSN solution (0.5 mg/mL) exceeded 45 C within 10 min, while the temperature of MSNs solution with a higher concentration (3 mg/mL) and water only increased to 28.5 C and 26.8 C, respectively. The photothermal conversion efficiency of bGNR@MSN was calculated following Roper's report [40, 41] to be 29.6% (See the Supporting Information for the detailed calculations). DOX loading was achieved by simply mixing DOX with bGNR@MSN-PEG. The loading efficiency was found to be pHdependent, as shown in Fig. 4b inset. At pH of 7.4, the average loading efficiency is 40.9% (w/w, 409 mg/g), which decreased to 21.4% (w/w, 214 mg/g) at pH of 5.3 due to higher pH enhanced the hydrophobic interaction between bGNR@MSN and DOX [13] . The DOX loading efficiency of bGNR@MSN-PEG was relatively high compared with conventional synthesized GNR@MSN-PEG (18.3%, 183 mg/g at pH of 7.4, Fig. S4 ) and many previously reported GNR@MSN nanocarriers (e.g., 7.0% at pH 7.4 reported by Baek et al. [8] ; 25.2% at pH 7.4 reported by Shen et al. [13] ; 11.4% at pH 7.4 reported by Liu et al. [15] ) owing to the larger pore size (4e8 nm), pore volume (1.65 cm 3 /g) and surface area (470 m 2 /g).
The release rate of DOX from bGNR@MSN(DOX) depended on the pH of the medium. Under acidic conditions, the release was accelerated because the daunosamine groups of DOX were protonated and the solubility of DOX increased [10] . Since the tumor extracellular environment and intracellular endosomes are acidic [42] , accelerated DOX released in acidic conditions could potentially improve the DOX delivery efficiency at the tumor site.
Nevertheless, less than 25% DOX was released from bGNR@MSN(DOX) within 6 h even at the pH of 5.3. Therefore, the photothermal effects of bGNR@MSN were used to further speed up the release of DOX. As shown in Fig. 4b , with a total 15 min NIR irradiation at power density of 0.5 W/cm 2 , the cumulative release of DOX increased from 24.5% to 55.5% within 6 h. High DOX loading efficiency as well as pH-sensitive and NIR-triggered release of DOX could potentially make bGNR@MSN one of the most promising candidates for enhanced the chemo-photothermal cancer therapy.
In vitro photothermal and chemo-photothermal therapy
In order to investigate the in vitro photothermal and chemophotothermal therapeutic effect of bGNR@MSN nanoplatforms, the cell viability after different treatment methods were measured by MTT viability assays (Fig. 4c ) and dead cells staining (Fig. 4d) . Without laser and DOX loading, as-synthesized bGNR@MSN had low cytotoxicity even at a high concentration of 1 mg/mL (Fig. S2) . However, the CTAC-capped GNRs killed more than 60% 4T1 cells at the same condition, which highlights the great enhancement of biocompatibility by coating the silica layer. Without the use of nanoparticles, the 808 nm laser alone at the power of 0.5 W/cm 2 only cause very limited thermal damage to the cells (Fig. 4d(i) ).
The efficacy of photothermal therapy alone (0.5 W/cm 2 , 5 min) was low at a low nanoparticles concentration (10 mg/mL) ( Fig. 4d(ii) ). The thermal therapeutic effects were greatly improved after increasing the concentration of bGNR@MSN (Fig. 4d(iii) :
40 mg/mL; (iv): 80 mg/mL) under the same laser illumination condition. For chemotherapy alone, we found that about 31.1% of cells were killed with the presence of 10 mg/mL DOX, as shown in Fig. 4c .
In contrast, at the same equivalent DOX concentration, synergistic chemo-photothermal therapy mediated by bGNR@MSN(DOX) killed >65% of cells ( Fig. 4c) with an NIR irradiation (0.5 W/cm 2 ,5 min), which showed about 2.3-fold and 4.5-fold enhancement in treatment efficacy over the pure chemotherapy or and photothermal treatment.
PET imaging and biodistribution studies
The deprotonated silanol groups (eSieO -) on the surface and inside the mesoporous pores of bGNR@MSN could be used as inherent hard oxygen donors for the stable chelator-free labeling of radioisotope 89 Zr as demonstrated in our previous studies [27, 34] . The results of TLC showed that about 68% of chelator-free 89 Zr labeling yield was achieved within the first 30 min incubation at Zr-bGNR@MSN(DOX)-PEG was estimated to be (9.2 ± 0.6) hours which was highly improved after PEGylation compared with the half-life (1.8 ± 0.3 h) of 89 Zr-bGNR@MSN(DOX) (Fig. S7) . The dominant radioactive signal from mice heart at the first 3 h p.i. clearly indicates the circulation of 89 Zr-bGNR@MSN(DOX)-PEG in mouse blood. Due to the over 100 nm hydrodynamic particle size, Zr-bGNR@MSN(DOX)-PEG tend to non-specifically accumulate to liver and spleen. After 6 h p.i., the 89 Zr-bGNR@MSN(DOX)-PEG were slowly cleared from blood circulation [43] . The average liver uptake of (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) (Fig. 5b) . The tumor uptake was 3.3 ± 0.5, 5.5 ± 1.1, 6.9 ± 1.1, 8.1 ± 0.6, 9.6 ± 0.9 and 8.6 ± 0.9 %ID/g at 0.5 h, 3 h, 6 h, 12 h, 24 h and 48 h, respectively (n ¼ 4, Fig. 5c ). Remarkably, the passive tumor targeting efficiency of 9.6 %ID/g at 24 h p. i. mediated by 89 ZrbGNR@MSN(DOX)-PEG was one of the highest tumor uptakes among all previously reported in vivo studies of GNRs based nanoplatforms [14, 29] . The biodistribution study of carried out at 24 h p. i. to validate the results from the PET imaging study. As shown in Fig. 5d , the biodistribution data and quantitative PET data matched well. The average tumor uptake was 8.6 %ID/g at 24 h p. i. The average spleen and liver uptake at 24 h p. i. were 25.1 ± 5.3 and 13.9 ± 5.1 %ID/g, respectively, as expected for i.v. injected nanoparticles with hydrodynamic diameters >10 nm, that are sequestered by the organs of the reticulo-endothelial system.
PA imaging of bGNR@MSN(DOX)-PEG
PA imaging with high spatial resolution, noninvasive deep tissue penetration and short scan time is a good complementary imaging modality for PET [32] . bGNR@MSN(DOX)-PEG nanoplatforms with high absorption in NIR range could be promising contrast agents for in vivo PA imaging. As shown in Fig. 6a and 24 h after i. v. injection of bGNR@MSN(DOX)-PEG, significant photoacoustic signal was observed from the tumor, which was clearly stronger than preinjection signal. The quantitative ROI analysis results of photoacoustic signal within the yellow circles (Fig. 6a) are shown in Fig. 6b . The signal at 24 p. i. time point is 4.7-fold stronger than preinjection.
Considering that PA imaging displays the actual location of the bGNR@MSN-PEG nanoparticles owing to the photoacoustic signals from GNRs, dual-modality PET/PA imaging further confirmed the enhanced accumulation of bGNR@MSN-PEG nanoplatforms in tumor, thereby providing multi-dimensional and more accurate information for the subsequent in vivo chemo-photothermal tumor therapy. Moreover, good correlation between the PET and PA images, further confirmed the excellent radiostability of 89 ZrbGNR@MSN(DOX)-PEG, validating their use as multimodal imaging agents.
In vivo chemo-photothermal therapy with NIR light
In vivo photothermal imaging was performed by 808 nm NIR laser irradiation, 24 h after i. v. injection of bGNR@MSN(DOX)-PEG in 4T1 tumor-bearing mice. The thermal images of tumor were visualized by a thermal camera, as shown in Fig. 6c . During the laser irradiation at a power density of 0.5 W/cm 2 , the tumor temperature increased rapidly and exceeded over 50 C within 1 min and reaching 60.2 C at the end of irradiation, which caused instantaneous and irreversible cell death in the tumors [13] . In contrast, without the injection of nanoplatforms, the temperate increased slowly and only reached 36.8 C after 5 min laser irradiation (Fig. 6c) . Taking advantages of excellent photothermal effects in vivo and NIR-triggered drug release, the chemo-photothermal treatments were performed when the average volume of 4T1 tumors reach 150 mm 3 on the flank of BALB/c mice (Fig. 7b) Fig. 7a and b) . 75% of the established 4T1 tumors in this group were eradicated completely by Day 21 as shown in the digital photographs of Fig. 7c without subsequent recurrence for six weeks (Fig. S3) . The significant enhancement in therapeutic efficacy observed here by combination chemo-photothermal treatment can be explained as follows: (1) while only a limited amount of DOX is released from the nanoplatforms at the physiological temperature, the release could be greatly enhanced under hyperthermia when exposed to NIR light; (2) local hyperthermia (~60 C) itself induces rapid and irreversible cancer cell death; and (3) potential enhancement in cytotoxicity by DOX at elevated temperatures, as reported previously [44] . The hematoxylin and eosin (H&E) staining was used to investigate the morphology and apoptosis in tumor tissues 24 h after different treatments as shown in Fig. 7d . The H&E staining results in chemo-photothermal therapy group showed most tumor cells damage among all five treatment groups which further confirmed results of tumor size and weight measurements in Fig. 7a and b . And the H&E stained images of major organs (heart, liver, kidney, spleen and lung) showed no noticeable organ damage or inflammatory lesions over 30 days (Fig. S9) , suggesting the low in vivo toxicity of bGNR@MSN(DOX)-PEG. Overall, the findings in this work indicate that the combination of photothermal therapy and chemotherapy by bGNR@MSN(DOX)-PEG nanoplatforms results in great enhancement in tumor treatment efficacy, over and above the therapeutic effects demonstrated by single modalities alone.
Conclusions
In summary, bacteria-like mesoporous silica-coated gold nanorods were successfully synthesized with significant enlarged pore size and surface area. After PEGylation, high efficient DOX loading and chelator-free 89 Zr radiolabeling, 89 Zr-bGNR@MSN(DOX)-PEG nanoplatforms served as both the contrast agents and therapeutic agents for PET and PA imaging-guided chemo-photothermal cancer therapy in vivo. PET imaging showed that bGNR@MSN(DOX)-PEG can passively target to tumor area with a high tumor accumulation (~10 %ID/g) based on EPR effect. The PA imaging results also confirmed the enhanced accumulation of bGNR@MSN(DOX)-PEG at the tumor site. Significantly enhanced therapeutic effects were achieved by bGNR@MSN(DOX)-PEG treatment under NIR laser irradiation when compared with single chemotherapy or photothermal therapy, which shows the promising and potential applications in future cancer diagnosis and therapy.
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